Table 3.
Clinical characteristics | Primary hMDS, N = 24 | Secondary MDS due to AA, N = 10 |
---|---|---|
Age (y) | 56 (16-83) | 59 (28-75) |
Karyotyping by MC | 11 | 5 |
Normal | 10 | 5 |
Abnormal | 3 | 0 |
No growth | ||
IPSS* | ||
Low risk (IPSS: low to int −1) | 2 | 4 |
High risk (IPSS: Int −2 and higher) | 19 | 6 |
Median survival (d) | 841 (37-2495) | 1360 (797-3185)†, P = .9 |
2133 (797-3185)‡, P = .009 | ||
Time to progression (range) | 234 (28-631) | 407 (167-1683), P = .0003 |
MDS indicates myelodysplastic syndrome; hMDS, hypocellular MDS; AA, aplastic anemia; IPSS, International Prognostic Scoring System; and MC, metaphase cytogenetics.
In 3 patients, there was no growth in MC hence IPSS not available;
from diagnosis of MDS; and
from diagnosis of AA.